Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

The role of moxifloxacin in tuberculosis therapy

Stephen H. Gillespie
European Respiratory Review 2016 25: 19-28; DOI: 10.1183/16000617.0085-2015
Stephen H. Gillespie
School of Medicine, University of St Andrews, St Andrews, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shg3@st-andrews.ac.uk
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Description of the design of three recent phase III clinical trials incorporating fluoroquinolone antibiotics in treatment-shortening regimens for pulmonary tuberculosis: REMoxTB [9], RIFAQUIN [10] and OFLOTUB [11]. Note that moxifloxacin/rifapentine 900 mg was administered twice weekly and moxifloxacin/rifapentine 1200 mg was administered weekly. H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; M: moxifloxacin; Rp: rifapentine (with a subscript defining dose); G: gatifloxacin; ep, mp, rp and hp: placebos for ethambutol, moxifloxacin, rifampicin and isoniazid, respectively; LJ: Lowenstein–Jensen; MGIT: Mycobacteria Growth Indicator Tube.

Tables

  • Figures
  • TABLE 1

    Summary of 4-month treatment trials in pulmonary tuberculosis, indicating their design, unfavourable rate and follow-up

    Study [ref.]Experimental regimen durationRegimensPatients on experimental arms nRelapse or unfavourable rate %Follow-up
    Second French study [79]18 weeks2SHRZ/HRZ180#324 months
    Mehrotra et al. [80]19 weeks3SHRZ/RH012 months
    3SHRZ/SHZ0
    3SHRZEmide5
    East African/British Medical Research Council [81]19 weeks2SHRZ/2HRZ1041624 months
    2SHRZ/2RH10411
    2SHRZ/2HZ9832
    2SHRZ/2H10530
    2HRZ/2H10040
    Singapore/British Medical Research Council [82]4 months2SHRZ/HRZ8011>24 months
    2SHRZ/HR816
    REMoxTB [9]17 weeks2MHRZ/2MHR6551512 months
    2EMRZ/2MR63620
    RIFAQUIN [10]4 months2MHRZ/2MRp (twice weekly)27518.212–18 months
    OFLOTUB [11]4 months2HRZG/2HR6942124 months
    • S: streptomycin; H: isoniazid; R: rifampicin; Z: pyrazinamide; Emide: ethionamide; M: moxifloxacin; E: ethambutol; Rp: rifapentine; G: gatifloxacin #: 204 patients in the trial and data analysed from 180.

PreviousNext
Back to top
View this article with LENS
Vol 25 Issue 139 Table of Contents
European Respiratory Review: 25 (139)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The role of moxifloxacin in tuberculosis therapy
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The role of moxifloxacin in tuberculosis therapy
Stephen H. Gillespie
European Respiratory Review Mar 2016, 25 (139) 19-28; DOI: 10.1183/16000617.0085-2015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The role of moxifloxacin in tuberculosis therapy
Stephen H. Gillespie
European Respiratory Review Mar 2016, 25 (139) 19-28; DOI: 10.1183/16000617.0085-2015
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Repurposing moxifloxacin
    • Early-phase development
    • Early-phase clinical studies of moxifloxacin
    • Phase III studies of fluoroquinolone-containing regimens for treatment shortening in susceptible TB
    • Safety of moxifloxacin-containing regimens
    • Observations on the outcome of phase III treatment-shortening trials
    • Moxifloxacin in the management of MDR-TB
    • New regimens and trials
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Diffuse parenchymal lung disease
  • Acute respiratory distress syndrome
  • Short-course treatment for MDR-TB: the STREAM trials
Show more Clinical Year in Review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society